Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sangqi Qingxuan Ointment versus losartan for prehypertension and grade 1 hypertension
ChiCTR2200064190Phase 2Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Sangqi Qingxuan in hypertension (HTN) and prehypertension (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: blood pressure. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
Sangqi Qingxuan
03
Conditions
hypertension (HTN)prehypertension
Beyond the preview
Go deeper on ChiCTR2200064190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064190.